ResourceLife Sciences
Evaluation of the anti-tumor efficacy of a EGFRxCD3 Bispecific in two novel in vivo systems
15 Mar 2021In this case study, The Jackson Laboratory evaluate the anti-tumor efficacy of the EGFRxCD3 Bispecific.
In this case study, The Jackson Laboratory evaluate the anti-tumor efficacy of the EGFRxCD3 Bispecific.